StockData

Organogenesis vs Xeris Biopharma

ORGO and XERS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ORGO and XERS compare

Xeris Biopharma is the larger company, worth 29 times as much as Organogenesis ($3.0B against $103M).

Xeris Biopharma grew revenue faster over the last twelve months (36.3% versus 6.5% for Organogenesis).

Xeris Biopharma keeps more of each dollar of sales as profit, with a net margin of −5.1% compared with −18.4% at Organogenesis.

Xeris Biopharma scores higher on the StockData Score (10 against 9 for Organogenesis), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricORGOXERS
Size and price
Market cap$103M$3.0B
Share price$0.803$16.70
Change, 1 year−87.1%130%
Change, 5 years−91.9%670%
Beta (5Y)0.590.28
Employees854435
StockData Score
Total score910 (better)
Valuation score1 (better)0
Growth score04 (better)
Performance score33
Health score5 (better)3
Dividend score00
Valuation
P/S0.2× (better)9.1×
P/B0.7×–
EV/EBITDA–83.7×
P/FCF5.0×–
FCF yield20.2%–
Growth
Revenue growth (TTM)6.5%36.3% (better)
Revenue growth, 5Y average10.8%70.2% (better)
EPS growth, 5Y average0.00%–
Profitability
Gross margin–86.6%
Operating margin−7.8%10.9% (better)
Net margin−18.4%−5.1% (better)
FCF margin4.6%–
Return on equity−44.1%–
Return on invested capital−21.7%22.1% (better)
Financial health
Debt / equity0.00–
Net debt / EBITDA–3.45
Interest coverage–1.3×
Current ratio3.52 (better)1.45
Altman Z-score1.263.31 (better)
Piotroski F-score58 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions53.2%59.4%
Held by insiders–5.2%
Insider net buying, 12 months−$988K (better)−$5.8M
Short interest, % of float–5.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.